Vienna, Austria

ESTRO 2023

Session Item

Saturday
May 13
15:15 - 16:30
Schubert
Dose escalation
Nathan Torelli, Switzerland;
Peter Hoskin, United Kingdom
1345
Symposium
Interdisciplinary
16:09 - 16:27
Where does SBRT stand in dose escalation? Is combination therapy with brachytherapy the optimal solution?
Andrew Loblaw, Canada
SP-0186

Abstract

Where does SBRT stand in dose escalation? Is combination therapy with brachytherapy the optimal solution?
Authors:

Andrew Loblaw1

1Sunnybrook Health Sciences Centre, Radiation Oncology, Toronto, Canada

Show Affiliations
Abstract Text

External beam radiotherapy, brachytherapy boost and androgen deprivation therapy is the evidence-based standard of care for unfavourable (unfavourable intermediate and high) risk prostate cancer.  The data supporting the use of elective whole pelvic radiotherapy is conflicting with the definitive study (NRG 0924) not expected to read out for another decade.

There are good data to support the use of stereotactic body radiotherapy (SBRT) in intermediate risk patients but limited data for unfavourable risk patients.  We will review the prospective studies that have been reported for these patients using SBRT as well as the studies that have been completed or are enrolling that will provide evidence for the use of SBRT (including the role of microboosting).